Sanofi has taken an important step forward in multiple myeloma management with Sarclisa Escena, an innovative subcutaneous formulation of isatuximab-irfc administered using the CirCLIQ on-body injector. The U.S. Food and Drug Administration granted approval on July 9, 2026, marking the first anticancer therapy approved for administration through an on-body injector. The milestone...